Suzhou Municipal Hospital

Innovent Initiates Phase 3 Trial of Picankibart for Psoriasis Patients with Inadequate IL-17 Response

- Innovent Biologics has dosed the first participant in a Phase 3 study evaluating picankibart, an anti-IL-23p19 antibody, for psoriasis patients who had inadequate response to prior IL-17 inhibitor treatment. - The randomized, double-blind trial will enroll approximately 310 participants to compare picankibart against continued IL-17 monoclonal antibody therapy, with the primary endpoint being skin clearance at week 16. - Previous Phase 2 data showed that 64.6% of patients with inadequate biologic response achieved skin lesion clearance after switching to picankibart, with response rates remaining stable through week 44. - The study addresses a critical unmet need, as real-world data indicates 28.5% of psoriasis patients discontinue IL-17 therapy due to primary failure and 24.3% experience secondary failure.